Bank Julius Baer & Co
SGMO

Bank Julius Baer & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bank Julius Baer & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,900
Closed -$18K – 846
2020
Q3 		$18K Sell
1,900
-600
-24% -$6.49K ﹤0.01% 664
2020
Q2 		$22K Hold
2,500
– – ﹤0.01% 600
2020
Q1 		$16K Buy
+2,500
New +$18.6K ﹤0.01% 588

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank Julius Baer & Co's SGMO Position: Q4 2020 in Review

Bank Julius Baer & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2020, closing a stake of 1,900 shares — an estimated $18K sold.

Bank Julius Baer & Co first reported a position in SGMO in Q1 2020 and held it in 3 quarters. The position peaked at $22K in Q2 2020. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Bank Julius Baer & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Bank Julius Baer & Co sold 1,900 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $18K.
  • Bank Julius Baer & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's SANGAMO THERAPEUTICS INC position peaked at $22K in Q2 2020.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Bank Julius Baer & Co's 13F filing for Q4 2020, filed 12 Feb 2021.